Molecular Interaction Fields and 3D-QSAR Studies of p53-MDM2 Inhibitors Suggest Additional Features of Ligand-Target Interaction
暂无分享,去创建一个
Matteo Magnani | Gabriele Cruciani | Andrea Carotti | Antonio Macchiarulo | Roberto Pellicciari | Massimo Baroni | Cristina Dezi | Alessandro Padova | G. Cruciani | Alessandro Padova | Massimo Baroni | R. Pellicciari | A. Macchiarulo | A. Carotti | Cristina Dezi | Matteo Magnani
[1] M. Walkinshaw,et al. The effects of phosphomimetic lid mutation on the thermostability of the N-terminal domain of MDM2. , 2010, Journal of molecular biology.
[2] Jonathan Y. Mane,et al. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions. , 2010, Journal of molecular graphics & modelling.
[3] Gabriele Cruciani,et al. Molecular fields in drug discovery: getting old or reaching maturity? , 2010, Drug discovery today.
[4] Shanghai Yu,et al. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. , 2009, Journal of medicinal chemistry.
[5] R. Pellicciari,et al. Targeting the conformational transitions of MDM2 and MDMX: Insights into key residues affecting p53 recognition , 2009, Proteins.
[6] Ernst Schönbrunn,et al. Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX* , 2009, The Journal of Biological Chemistry.
[7] Chong Li,et al. Apamin as a template for structure-based rational design of potent peptide activators of p53. , 2009, Angewandte Chemie.
[8] Xin Huang,et al. Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. , 2009, Journal of medicinal chemistry.
[9] A. Hopfinger,et al. The receptor-dependent QSAR paradigm: an overview of the current state of the art. , 2009, Medicinal chemistry (Shariqah (United Arab Emirates)).
[10] M. Walkinshaw,et al. Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif , 2009, Journal of chemical biology.
[11] R. Pellicciari,et al. MDM2/MDMX inhibitor peptide: WO2008106507 , 2009, Expert opinion on therapeutic patents.
[12] R. V. van Montfort,et al. Structure-based design of molecular cancer therapeutics. , 2009, Trends in biotechnology.
[13] A. Dömling. Hot, hotter, hottest , 2009, Cell cycle.
[14] Nir Ben-Tal,et al. Study of MDM2 Binding to p53-Analogues: Affinity, Helicity, and Applicability to Drug Design , 2009, J. Chem. Inf. Model..
[15] Shaomeng Wang,et al. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. , 2009, Annual review of pharmacology and toxicology.
[16] Chong Li,et al. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX , 2009, Proceedings of the National Academy of Sciences.
[17] D. Hadjipavlou-Litina,et al. Chalcones in cancer: understanding their role in terms of QSAR. , 2009, Current medicinal chemistry.
[18] F. Mancini,et al. MDM4 (MDMX) and its Transcript Variants , 2009, Current genomics.
[19] G. Wahl,et al. Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry? , 2009, Molecular Cancer Research.
[20] John A. Robinson,et al. 1 Thermodynamic and Computational Studies on the Binding of p 53-Derived Peptides and Peptidomimetic Inhibitors to HDM 2 , 2009 .
[21] Gabriele Cruciani,et al. Targeting the Conformational Transitions of MDM2 and MDMX: Insights into Dissimilarities and Similarities of p53 Recognition , 2008, J. Chem. Inf. Model..
[22] Shubhra Ghosh Dastidar,et al. Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. , 2008, Journal of the American Chemical Society.
[23] Peter Gedeck,et al. Exploiting QSAR models in lead optimization. , 2008, Current opinion in drug discovery & development.
[24] Small molecule inhibitors of the p53-MDM2. , 2008, Current medicinal chemistry.
[25] L. M. Espinoza-Fonseca,et al. Aromatic-aromatic interactions in the formation of the MDM2-p53 complex. , 2008, Biochemical and biophysical research communications.
[26] Shaomeng Wang,et al. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer , 2008, Molecular Cancer Therapeutics.
[27] Hongma Sun,et al. Pharmacophore-based virtual screening. , 2008, Current medicinal chemistry.
[28] H. Schünemann,et al. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties , 2008, Journal of Molecular Medicine.
[29] Dajun Yang,et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition , 2008, Proceedings of the National Academy of Sciences.
[30] A. Unterberg,et al. Uniform MDM 2 Overexpression in a Panel of Glioblastoma Multiforme Cell Lines with Divergent EGFR and p 53 Expression Status , 2008 .
[31] Mark R Player,et al. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. , 2008, Expert opinion on investigational drugs.
[32] Stephen R. Johnson,et al. The Trouble with QSAR (or How I Learned To Stop Worrying and Embrace Fallacy) , 2008, J. Chem. Inf. Model..
[33] Christopher L. McClendon,et al. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.
[34] Deepak Srinivasan,et al. Modulation of the p53-MDM2 Interaction by Phosphorylation of Thr18: A Computational Study , 2007, Cell cycle.
[35] M. Dyer,et al. Targeting MDM2 and MDMX in retinoblastoma. , 2007, Current cancer drug targets.
[36] Claudio N. Cavasotto,et al. Ligand docking and structure-based virtual screening in drug discovery. , 2007, Current topics in medicinal chemistry.
[37] Ray Luo,et al. Binding induced folding in p53-MDM2 complex. , 2007, Journal of the American Chemical Society.
[38] Jürgen Bajorath,et al. Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches. , 2007, Drug discovery today.
[39] Gabriele Cruciani,et al. A Common Reference Framework for Analyzing/Comparing Proteins and Ligands. Fingerprints for Ligands And Proteins (FLAP): Theory and Application , 2007, J. Chem. Inf. Model..
[40] L. Vassilev,et al. MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.
[41] Baoli Hu,et al. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. , 2007, Cancer research.
[42] G. Wahl,et al. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.
[43] Michael A. Dyer,et al. Inactivation of the p53 pathway in retinoblastoma , 2006, Nature.
[44] J. Trujillo-Ferrara,et al. Conformational changes of the p53-binding cleft of MDM2 revealed by molecular dynamics simulations. , 2006, Biopolymers.
[45] Per Källblad,et al. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. , 2006, Journal of medicinal chemistry.
[46] C. Schubert,et al. Crystallographic analysis of an 8-mer p53 peptide analogue complexed with MDM2. , 2006, Journal of the American Chemical Society.
[47] Gerald M. Maggiora,et al. On Outliers and Activity Cliffs-Why QSAR Often Disappoints , 2006, J. Chem. Inf. Model..
[48] Su Qiu,et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. , 2006, Journal of medicinal chemistry.
[49] R. Nussinov,et al. Comparison of the human and worm p53 structures suggests a way for enhancing stability. , 2006, Biochemistry.
[50] John A. Robinson,et al. Structure – Activity Studies in a Family of b-Hairpin Protein Epitope Mimetic Inhibitors of the p 53 – HDM 2 Protein – Protein Interaction , 2006 .
[51] Paul N Barlow,et al. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. , 2005, Journal of molecular biology.
[52] Maxwell D Cummings,et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. , 2005, Journal of medicinal chemistry.
[53] H. Carlson,et al. Computational studies and peptidomimetic design for the human p53–MDM2 complex , 2004, Proteins.
[54] David C Fry,et al. NMR structure of a complex between MDM2 and a small molecule inhibitor , 2004, Journal of biomolecular NMR.
[55] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[56] Ajay N. Jain. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. , 2003, Journal of medicinal chemistry.
[57] Wolfgang Sippl,et al. Development of biologically active compounds by combining 3D QSAR and structure-based design methods , 2002, J. Comput. Aided Mol. Des..
[58] D. Abraham,et al. QSAR: Hydropathic analysis of inhibitors of the p53–mdm2 interaction , 2001, Proteins.
[59] C. Renner,et al. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. , 2001, Biochemistry.
[60] P. Furet,et al. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. , 2000, Journal of medicinal chemistry.
[61] Hsiao-Huei Wu,et al. MDM2--master regulator of the p53 tumor suppressor protein. , 2000, Gene.
[62] W. L. Jorgensen,et al. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .
[63] A. Levine,et al. Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.
[64] C. Arrowsmith,et al. New insights into p53 function from structural studies. , 1996, Oncogene.
[65] A. Marchetti,et al. mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. , 1995, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[66] Anton J. Hopfinger,et al. Application of Genetic Function Approximation to Quantitative Structure-Activity Relationships and Quantitative Structure-Property Relationships , 1994, J. Chem. Inf. Comput. Sci..
[67] S. Stass,et al. The human MDM-2 oncogene is overexpressed in leukemias. , 1993, Blood.
[68] G. Reifenberger,et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. , 1993, Cancer research.
[69] P. Meltzer,et al. Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.
[70] J. Freidman,et al. Multivariate adaptive regression splines , 1991 .
[71] P. Goodford. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.